Louisiana 2018 Regular Session

Louisiana Senate Bill SB285

Introduced
3/1/18  
Introduced
3/1/18  
Refer
3/1/18  
Refer
3/12/18  
Report Pass
4/11/18  
Report Pass
4/11/18  
Engrossed
4/17/18  
Engrossed
4/17/18  
Refer
4/18/18  
Refer
4/18/18  
Report Pass
4/25/18  
Report Pass
4/25/18  
Enrolled
5/15/18  
Enrolled
5/15/18  
Chaptered
5/20/18  
Chaptered
5/20/18  

Caption

Prohibits a health insurance issuer from denying a nonopioid prescription in favor of an opioid prescription. (8/1/18)

Impact

By enacting SB 285, Louisiana's laws would enforce greater protections for patients suffering from chronic pain, giving them access to preferred nonopioid treatments without the risk of insurance denial in favor of opioids. This legislation aligns with national trends aimed at reducing opioid dependence and promoting safer pain management solutions—a significant public health concern in recent years. The bill may significantly change how insurance companies process chronic pain prescriptions, affecting both healthcare providers and patients in the state.

Summary

Senate Bill 285 aims to legislate the handling of prescriptions for chronic pain, specifically focusing on health insurance provisions. The bill prohibits health insurance issuers from denying coverage for nonopioid prescriptions when a licensed physician prescribes them, which supports the increasing focus on nonopioid pain management alternatives amid the opioid crisis. It also ensures that, if an opioid prescription is deemed medically necessary, insurers cannot substitute it for alternative medications that may be less effective or require larger quantities.

Sentiment

The general sentiment surrounding SB 285 appears to be supportive, particularly from healthcare advocates and patient rights groups. These stakeholders view the bill as a proactive measure against the ongoing opioid epidemic, promoting safer alternatives for managing chronic pain. However, there may be concerns from some insurance providers about the financial implications of increased coverage for nonopioid prescriptions, indicating a potential divide between patient advocacy and insurance industry interests.

Contention

Notable points of contention likely revolve around the balance of power between patient care and insurance company practices. Some may argue that the bill could impose undue constraints on insurers, affecting their ability to manage costs. Additionally, there could be a debate regarding the definition of 'medical necessity' when it comes to prescriptions, which may lead to differing interpretations and disputes in coverage decisions. Ensuring that the implementation of SB 285 meets the intended goals of patient safety without creating complications in the healthcare system could be a central challenge.

Companion Bills

No companion bills found.

Similar Bills

CA AB2789

Health care practitioners: prescriptions: electronic data transmission.

CA AB852

Health care practitioners: electronic prescriptions.

CA AB149

Controlled substances: prescriptions.

TX HB2246

Relating to certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX SB594

Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX HB2766

Relating to electronic and other controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.